SB
LYRA

Samsara BioCapital’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Samsara BioCapital’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,803
Closed -$176K – 36
2025
Q1 		$176K Sell
27,803
-11,511
-29% -$108K 0.03% 33
2024
Q4 		$406K Sell
39,314
-16,291
-29% -$179K 0.06% 38
2024
Q3 		$715K Hold
55,605
– – 0.14% 35
2024
Q2 		$769K Hold
55,605
– – 0.16% 33
2024
Q1 		$17.3M Hold
55,605
– – 2.68% 8
2023
Q4 		$14.6M Hold
55,605
– – 2.27% 11
2023
Q3 		$10.9M Hold
55,605
– – 3.33% 8
2023
Q2 		$11.4M Buy
55,605
+20,060
+56% +$2.79M 2.01% 10
2023
Q1 		$3.57M Hold
35,545
– – 0.74% 25
2022
Q4 		$5.58M Hold
35,545
– – 1.2% 18
2022
Q3 		$8.9M Hold
35,545
– – 2.08% 13
2022
Q2 		$10M Buy
+35,545
New +$9.68M 2.68% 7

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital's LYRA Position: Q2 2025 in Review

Samsara BioCapital sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 27,803 shares — an estimated $176K sold.

Samsara BioCapital first reported a position in LYRA in Q2 2022 and held it in 12 quarters. The position peaked at $17.3M in Q1 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • Samsara BioCapital reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Samsara BioCapital sold 27,803 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $176K.
  • Samsara BioCapital first reported a position in LYRA THERAPEUTICS INC in Q2 2022 and held it in 12 quarters.
  • Samsara BioCapital's LYRA THERAPEUTICS INC position peaked at $17.3M in Q1 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.